1 completed, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Extra-Adrenal Paraganglioma: new trials by email Literature Review of Extra-Adrenal Paraganglioma trials Research Report on Extra-Adrenal Paraganglioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma Laboratory Biomarker Analysis, Pazopanib Hydrochloride - Extra-Adrenal Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 7 | 2011-05-01 | 2017-09-21 |
| RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid RAD001 - Pheochromocytoma, Extra-adrenal Paraganglioma | Phase 2 | Completed | Seoul National University Hospital | 33 | 2008-07-01 | 2015-05-20 |
Paraganglioma, Extra-Adrenal (2) · Pheochromocytoma (2) · Paraganglioma (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Paraganglioma (1)
Everolimus (1) · pazopanib (1)
National Cancer Institute (NCI) (1) · Seoul National University Hospital (1)
Hong Kong (1) · Singapore (1) · South Korea (1) · United States (1)
Do-Youn Oh, MD, PhD (1) · Keith Bible (1) · Yung-Jue Bang, MD, PhD (1)
N01CM00039 (1), N01CM00099 (1), N01CM62205 (1), P30CA015083 (1)